Montes Archimedes Acquisition (ROIV)
(Real Time Quote from BATS)
$11.26 USD
+0.08 (0.72%)
Updated May 14, 2024 02:52 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ROIV 11.26 +0.08(0.72%)
Will ROIV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ROIV
Stock Market News for Nov 14, 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
Other News for ROIV
Roivant Sciences (ROIV) Receives a Buy from Piper Sandler
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Buy Rating Justified by Roivant Sciences’ Strategic Positioning and Promising Drug Pipeline
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Roivant Sciences put volume heavy and directionally bearish